ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0966

Integrated Single Cell RNA-Sequencing Analysis of Tissue-Localized T Cells in Cutaneous Lupus and Lupus Nephritis
Abstract Number: 0050

Integrative Analysis of mRNAs to Identify Sex Differences in Th-17 Mediated Inflammation in Ankylosing Spondylitis
Abstract Number: 1128

Inter-relationships Between Multiple Joint Osteoarthritis and Collagen Biomarkers in Men: The Johnston County Osteoarthritis Project
Abstract Number: 1647

Interaction Effect of Systemic Inflammation and Dietary Protein Intake on Resting Energy Expenditure in Individuals with RA
Abstract Number: 1908

Interferon (IFN)-Stimulated Gene 15: A Novel Biomarker for Lymphoma Development in Sjögren’s Syndrome
Abstract Number: 0528

Interferon Pathway Lupus Risk Alleles Modulate Risk of Death from Acute COVID-19
Abstract Number: 1770

Interim Analysis of Cohort 1 in the Mesenchymal Stromal Cell Trial in Systemic Lupus Erythematosis: Safety and Data Management During the Pandemic
Abstract Number: 0127

Interleukin 1 Receptor Antagonist (IL-1Ra) Variable Number of Tandem Repeat (VNTR) Polymorphism in Fibromyalgia Patients in South India
Abstract Number: 1131

Interleukin 6 Concentration in Synovial Fluid and Its Clinical Significance
Abstract Number: 1577

Interleukin-37: Associations of Plasma Levels and Genetic Variants in Gout
Abstract Number: 0030

Interleukin-9 Enhances the Osteoclastogenesis in Rheumatoid Arthritis
Abstract Number: 1318

Interplay Between Covid-19 and Spondyloarthritis or Its Treatment
Abstract Number: 0430

Interstitial Lung Disease in ANCA-Associated Vasculitis: Associated Factors and Outcomes
Abstract Number: 0752

Intervening on Adverse Childhood Experiences in SLE—Self-Efficacy as a Potential Target
Abstract Number: 0623

Intervention to Improve SLE Medication Adherence

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].